ATO-101 (211At-labeled girentuximab) / ATONCO, Telix - LARVOL DELTA

Evaluation of Safety, Tolerability and Response of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Institut Cancerologie de l'Ouest

First-in-human • New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor